Background: Non-Hodgkins lymphoma (NHL) is a heterogeneous group of malignancies, originating in thelymphatic organs, whose incidence is increasing in developed as well as developing countries. Epidemiologicalevidence suggests that aspirin may reduce the incidence and mortality of several cancers. The main objectiveof this study was to evaluate the potential relationship between using aspirin and development of NHL with ameta-analysis. Materials and
Methods: A total of 7 studies were included. Outcome was calculated and reportedas odds ratios (ORs). Heterogeneity was assessed with Cochrane Q and I2 statistics. Dissemination bias wasevaluated by funnel plot visualization and trim-and-fill analysis.
Results: Our analysis showed OR of developingNHL overall of 1(95% CI: 0.87-1.16, p=0.9), and in females this was 0.81 (95%CI: 0.72-.92, p=0.001) and inmales 1.01 (95%CI: 0.82-1.26, p=0.86). The odds ratio (OR) of chronic lymphocytic leukemia/small lymphocyticlymphoma (CLL/SLL) was 0.85 (95%CI: 0.75-0.97, p=0.02), The ORs of follicular lymphoma (FL) and largeB-cell lymphoma (DLBCL) in individuals exposed to aspirin were 1.12 (95%CI: 0.86-1.45, p=0.37) and 1.03(95%CI: 0.9-1.19, p=0.6) respectively.
Conclusions: In conclusion, individuals taking aspirin do not demonstrateany change in risk of Non-Hodgkins lymphoma.